BRIEF published on 11/19/2024 at 07:08, 2 days 6 hours ago Siegfried ouvre un nouveau centre de recherche et développement de substances médicamenteuses à Evionnaz Industrie Pharmaceutique Siegfried AG Substances Médicamenteuses Evionnaz Centre De R&D
BRIEF published on 11/19/2024 at 07:08, 2 days 6 hours ago Siegfried Opens New R&D Center for Drug Substances in Evionnaz Pharmaceutical Industry Siegfried AG Drug Substances R&D Center Evionnaz
PRESS RELEASE published on 11/19/2024 at 07:03, 2 days 6 hours ago Siegfried opens new global R&D Center for Drug Substances in Evionnaz Siegfried inaugurates new R&D Center for Drug Substances in Evionnaz, Switzerland, enhancing global development capabilities and supporting EVOLVE+ strategy Pharmaceutical Industry Drug Substances Siegfried R&D Center Evionnaz
BRIEF published on 11/12/2024 at 06:35, 9 days 6 hours ago DINAMIQS s'agrandit avec un nouveau laboratoire à Zurich Thérapie Cellulaire Et Génique Bio-Technopark Zurich Laboratoire DINAMIQS Extension Siegfried Fabrication De Vecteurs Viraux
BRIEF published on 11/12/2024 at 06:35, 9 days 6 hours ago DINAMIQS Expands with New Lab in Zurich Cell And Gene Therapy DINAMIQS Lab Siegfried Expansion Viral Vector Manufacturing Bio-Technopark Zurich
PRESS RELEASE published on 11/12/2024 at 06:30, 9 days 6 hours ago DINAMIQS opens new lab in Zurich Siegfried's subsidiary DINAMIQS opens new state-of-the-art lab in Zurich Bio-Technopark, strengthening offerings in cell and gene therapy market Cell And Gene Therapy Zurich Siegfried DINAMIQS Lab
BRIEF published on 10/24/2024 at 06:35, 28 days 6 hours ago Siegfried AG Unveils EVOLVE+ Strategy for Sustained Growth Operational Excellence Strategic Development Pharmaceutical Growth EVOLVE+ Strategy CDMO Expansion
BRIEF published on 10/24/2024 at 06:35, 28 days 6 hours ago Siegfried AG dévoile sa stratégie EVOLVE+ pour une croissance durable Excellence Opérationnelle Développement Stratégique Croissance Pharmaceutique Stratégie EVOLVE+ Agrandissement Du CDMO
PRESS RELEASE published on 10/24/2024 at 06:30, 28 days 6 hours ago Strategy EVOLVE+ paves the way for continued profitable growth Siegfried unveils EVOLVE+ strategy at Capital Markets Day, focusing on growth, technology, and operational excellence. CEO emphasizes company's strong position in the CDMO market CDMO Strategy Growth Siegfried EVOLVE+
BRIEF published on 09/04/2024 at 06:35, 2 months 17 days ago EGS Beteiligungen AG Increases Stake in Siegfried to 7.2% Registered Shares Convertible Bond Shareholding Increase EGS Beteiligungen AG Pharmaceutical Acquisition Siegfried Holding
Published on 11/21/2024 at 13:00, 11 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 11 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 11 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 11 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 11 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 36 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 56 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 41 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 06:58, 6 hours 13 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 13 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 13 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 17 hours 3 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 51 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
